PL3354277T3 - Kompozycje i sposoby leczenia choroby gauchera - Google Patents
Kompozycje i sposoby leczenia choroby gaucheraInfo
- Publication number
- PL3354277T3 PL3354277T3 PL18161509T PL18161509T PL3354277T3 PL 3354277 T3 PL3354277 T3 PL 3354277T3 PL 18161509 T PL18161509 T PL 18161509T PL 18161509 T PL18161509 T PL 18161509T PL 3354277 T3 PL3354277 T3 PL 3354277T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- gaucher disease
- treating gaucher
- treating
- Prior art date
Links
- 208000015872 Gaucher disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2442—Chitinase (3.2.1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01014—Chitinase (3.2.1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22919509P | 2009-07-28 | 2009-07-28 | |
| US30304410P | 2010-02-10 | 2010-02-10 | |
| US31751310P | 2010-03-25 | 2010-03-25 | |
| US33337210P | 2010-05-11 | 2010-05-11 | |
| US35933810P | 2010-06-28 | 2010-06-28 | |
| PCT/US2010/043586 WO2011017177A1 (en) | 2009-07-28 | 2010-07-28 | Compositions and methods for treating gaucher disease |
| EP18161509.7A EP3354277B1 (en) | 2009-07-28 | 2010-07-28 | Compositions and methods for treating gaucher disease |
| EP10806936.0A EP2459212B1 (en) | 2009-07-28 | 2010-07-28 | Compositions and methods for treating gaucher disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3354277T3 true PL3354277T3 (pl) | 2021-12-13 |
Family
ID=43527246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18161509T PL3354277T3 (pl) | 2009-07-28 | 2010-07-28 | Kompozycje i sposoby leczenia choroby gauchera |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20110027254A1 (pl) |
| EP (2) | EP2459212B1 (pl) |
| JP (5) | JP5815521B2 (pl) |
| CN (3) | CN105126086B (pl) |
| AU (3) | AU2010281403B2 (pl) |
| CA (2) | CA2768999C (pl) |
| CO (1) | CO6660423A2 (pl) |
| ES (2) | ES2668079T3 (pl) |
| IL (3) | IL262668B2 (pl) |
| MX (3) | MX2012001268A (pl) |
| NZ (3) | NZ713967A (pl) |
| PL (1) | PL3354277T3 (pl) |
| RU (2) | RU2568831C2 (pl) |
| WO (1) | WO2011017177A1 (pl) |
| ZA (2) | ZA201200704B (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| WO2007092829A2 (en) | 2006-02-07 | 2007-08-16 | Shire Human Genetic Therapies, Inc. | Stabilized compositions of proteins having a free thiol moiety |
| ES2385735T3 (es) | 2008-06-26 | 2012-07-31 | Orphazyme Aps | Uso de Hsp70 como regulador de la actividad enzimática |
| RU2568831C2 (ru) | 2009-07-28 | 2015-11-20 | Шайр Хьюман Дженетик Терапиз | Композиции и способы для лечения болезни гоше |
| US9453847B2 (en) | 2010-07-19 | 2016-09-27 | Shire Human Genetic Therapies, Inc. | Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof |
| RU2013125923A (ru) | 2010-11-30 | 2015-01-10 | Орфазиме Апс | СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70 |
| US9387236B2 (en) * | 2011-06-10 | 2016-07-12 | Prothera Inc. | Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases |
| CN107880123A (zh) | 2011-10-28 | 2018-04-06 | 普罗典娜生物科学有限公司 | 识别α‑突触核蛋白的人源化抗体 |
| AU2013211874B2 (en) | 2012-01-27 | 2017-11-02 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| KR102096752B1 (ko) | 2012-03-02 | 2020-04-02 | 샤이어 휴먼 지네틱 테라피즈 인크. | Ｉｉｉ형 고셔병을 치료하기 위한 조성물 및 방법 |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| DK3193840T3 (da) | 2014-09-15 | 2021-08-16 | Orphazyme As | Arimoclomol-formulering |
| WO2017053605A1 (en) * | 2015-09-22 | 2017-03-30 | Saint Louis University | Iminosugars for improving bone mineral density in bone disease |
| US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| DK3782624T3 (da) | 2016-04-29 | 2025-12-15 | Zevra Denmark As | Arimoclomol til behandling af glucocerebrosidase-associerede lidelser |
| EP3264092A1 (en) * | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
| EP3700526A4 (en) * | 2017-10-26 | 2021-09-08 | Takeda Pharmaceutical Company Limited | FORMULATIONS WITH GLUCOCEREBROSIDASE AND ISOFAGOMIN |
| JP2021525711A (ja) * | 2018-05-27 | 2021-09-27 | バイオアシス テクノロジーズ インコーポレイテッド | ゴーシェ病の処置 |
| US12286400B2 (en) | 2019-04-25 | 2025-04-29 | Takeda Pharmaceutical Company Limited | Isofagomine salts, methods of use and formulations |
| WO2021022045A1 (en) | 2019-07-31 | 2021-02-04 | Ecolab Usa Inc. | Personal protective equipment free delimer compositions |
| RU2759054C2 (ru) * | 2019-11-27 | 2021-11-09 | федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) | Рекомбинантный штамм вируса гриппа A/PR8-NS124-Luc и способ оценки поствакцинальных нейтрализующих антител с использованием биолюминесцентной детекции |
| KR20230002792A (ko) * | 2020-04-23 | 2023-01-05 | 우시 바이올로직스 아일랜드 리미티드 | 만노스-말단 n-글리칸을 갖는 재조합 당단백질을 생산하는 유전적으로 변형된 세포주 |
| WO2021260120A1 (en) * | 2020-06-24 | 2021-12-30 | Orphazyme A/S | Arimoclomol for treating gaucher disease |
| EP4179332A1 (en) * | 2020-07-13 | 2023-05-17 | Genentech, Inc. | Cell-based methods for predicting polypeptide immunogenicity |
| WO2022072888A1 (en) * | 2020-10-01 | 2022-04-07 | Sangamo Therapeutics, Inc. | Methods of detecting anti-aav antibodies |
| EP4247792A1 (en) | 2020-11-19 | 2023-09-27 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5241093B2 (pl) | 1973-05-16 | 1977-10-17 | ||
| US4925796A (en) * | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US5272066A (en) * | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
| EP0393143A4 (en) | 1987-12-23 | 1991-09-11 | Us Commerce | Cloned dna for synthesizing unique glucocerebrosidase |
| DE68926569T2 (de) | 1988-12-23 | 1996-09-26 | Genzyme Corp | Cho-zellen befähigt enzymatisch aktive rekombinante-glukocerebrosidase zu produzieren |
| US5549892A (en) * | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| US5236838A (en) * | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| JPH03503721A (ja) | 1988-12-23 | 1991-08-22 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| WO1992013067A1 (en) | 1991-01-21 | 1992-08-06 | Genzyme Corporation | Production of enzymatically active glucocerebrosidase from recombinant cells |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| AU5743994A (en) | 1992-12-10 | 1994-07-04 | Enzon, Inc. | Glycolipid enzyme-polymer conjugates |
| AU6809494A (en) | 1992-12-21 | 1994-07-19 | Enzon, Inc. | Purification of proteinaceous material |
| JP3002113B2 (ja) | 1994-03-30 | 2000-01-24 | 寳酒造株式会社 | 糖質又は複合糖質の製造方法 |
| DE69521074T2 (de) | 1994-03-30 | 2001-09-13 | Takara Shuzo Co., Ltd. | Transglykosylierungsverfahren zur Herstellung eines Kohlenhydrats oder eines Glykokonjugates |
| US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| SI1516628T1 (sl) | 1995-07-27 | 2013-10-30 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| ATE426031T1 (de) | 1995-09-14 | 2009-04-15 | Virginia Tech Intell Prop | Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen |
| JP2002504083A (ja) | 1996-03-05 | 2002-02-05 | オーケスト インコーポレイテッド | ヒアルロン酸および増殖因子による骨の増殖を促進する方法 |
| US6177447B1 (en) | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| PL190041B1 (pl) | 1996-09-13 | 2005-10-31 | Transkaryotic Therapies | Zastosowanie ludzkiej komórki, cząsteczka DNA, konstrukt ekspresji, hodowana ludzka komórka, klonujący szczep komórek, klonująca linia komórek, białko, sposób wytwarzania glikozylowanej ludzkiej alfa-galaktozydazy A, oczyszczona glikozylowana ludzkaalfa-galaktozydaza A, sposób oczyszczania ludzkiej alfa-galaktozydazy A, zastosowanie oczyszczonej glikozylowanej ludzkiej alfa-galaktozydazy A, kompozycja terapeutyczna i sposób oczyszczania ludzkiej alfa-galaktozydazy A z próbki |
| IL155588A0 (en) | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| JPH10273500A (ja) | 1997-03-03 | 1998-10-13 | Noguchi Inst | 複合糖ペプチド及びその製造法 |
| JPH10306099A (ja) | 1997-03-04 | 1998-11-17 | Noguchi Inst | 新規複合糖ペプチドおよびその製法 |
| TW542721B (en) | 1997-08-06 | 2003-07-21 | Melaleuca Inc | Dietary supplements containing natural ingredients |
| DE69835308T2 (de) | 1997-08-07 | 2007-08-09 | University Of Utah Research Foundation, Salt Lake City | Prodrugs und Konjugate von Selenoenthaltenden Verbindungen und ihre Verwendung |
| US5939279A (en) * | 1997-09-18 | 1999-08-17 | The Board Of Trustees Of The University Of Arkansas | Inhibition of bacterial binding by high-mannose oligosaccharides |
| JP2001526239A (ja) | 1997-12-22 | 2001-12-18 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | 角質細胞増殖因子−２製剤 |
| GB9802249D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
| GB9807464D0 (en) | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
| EP0976838A1 (en) | 1998-05-06 | 2000-02-02 | Rhone-Poulenc Nutrition Animale | Enzymes mixture |
| JPH11318441A (ja) | 1998-05-14 | 1999-11-24 | Nagase & Co Ltd | 超耐熱耐酸性アミロプルラナーゼ |
| KR19990086271A (ko) | 1998-05-27 | 1999-12-15 | 손경식 | 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제 |
| AU4045599A (en) | 1998-06-05 | 1999-12-30 | Aventis Pharma S.A. | Polypeptides with beta-secretase type activity |
| DK1137789T3 (da) | 1998-12-09 | 2010-11-08 | Phyton Holdings Llc | Fremgangsmåde til fremstilling af et glycoprotein med glycosylering af human type |
| GB9909066D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| AU5483600A (en) * | 1999-06-11 | 2001-01-02 | Jean A. Chmielewski | Pharmaceutical materials and methods for their preparation and use |
| AU6050600A (en) | 1999-07-26 | 2001-02-13 | G.D. Searle & Co. | Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidaseenzyme for the manufacture of medicament for the treatment of glycolipid storag e diseases |
| US6770468B1 (en) * | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
| US6534300B1 (en) * | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| IL149008A0 (en) | 1999-10-04 | 2002-11-10 | Chiron Corp | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| AU2352201A (en) | 1999-12-30 | 2001-07-16 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| CN1156702C (zh) * | 2001-07-11 | 2004-07-07 | 上海晶泰生物技术有限公司 | 采用标记链霉亲和素-生物素技术的蛋白质芯片 |
| EP1452597A4 (en) | 2001-12-04 | 2006-09-20 | Mitsubishi Pharma Corp | PROCESS FOR ACTIVATING PROTEIN |
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| US7429460B2 (en) * | 2003-01-15 | 2008-09-30 | Yeda Research And Development Co., Ltd. | Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| EP2444102B1 (en) | 2003-01-31 | 2015-04-08 | The Mount Sinai School of Medicine of New York University | Combination therapy for treating protein deficiency disorders |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| ZA200608572B (en) * | 2004-04-16 | 2008-06-25 | Genentech Inc | Assay for antibodies |
| US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| US7385028B2 (en) | 2004-12-22 | 2008-06-10 | Ambrx, Inc | Derivatization of non-natural amino acids and polypeptides |
| BRPI0614100A2 (pt) | 2005-08-03 | 2011-03-09 | Immunogen Inc | formulações de imunoconjugado lìquidas |
| WO2007092829A2 (en) | 2006-02-07 | 2007-08-16 | Shire Human Genetic Therapies, Inc. | Stabilized compositions of proteins having a free thiol moiety |
| JP2009529885A (ja) * | 2006-03-17 | 2009-08-27 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム酵素に対する抗体の検出のためのアッセイ |
| BRPI0709617A2 (pt) * | 2006-04-18 | 2011-07-19 | Ekr Therapeutics Inc | composição farmacêutica, e, métodos para tratar elevações agudas de pressão sangüìnea em um indivìduo humano, para induzir a hipotensão em um indivìduo humano, e para produzir uma composição farmacêutica para administração intravenosa |
| DK1860101T3 (da) | 2006-05-24 | 2011-07-25 | Amicus Therapeutics Inc | Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf |
| AU2007260812B2 (en) * | 2006-06-23 | 2012-08-16 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase |
| DK2041270T3 (da) * | 2006-07-13 | 2014-01-27 | Wyeth Llc | Fremstilling af glycoproteiner |
| TWI489984B (zh) * | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| RU2568831C2 (ru) | 2009-07-28 | 2015-11-20 | Шайр Хьюман Дженетик Терапиз | Композиции и способы для лечения болезни гоше |
| US20130017169A1 (en) | 2010-03-02 | 2013-01-17 | Protalix Ltd. | Multimeric forms of therapeutic proteins and uses thereof |
| US9453847B2 (en) | 2010-07-19 | 2016-09-27 | Shire Human Genetic Therapies, Inc. | Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof |
-
2010
- 2010-07-28 RU RU2012107103/15A patent/RU2568831C2/ru active
- 2010-07-28 EP EP10806936.0A patent/EP2459212B1/en active Active
- 2010-07-28 MX MX2012001268A patent/MX2012001268A/es active IP Right Grant
- 2010-07-28 IL IL262668A patent/IL262668B2/en unknown
- 2010-07-28 CN CN201510580649.XA patent/CN105126086B/zh active Active
- 2010-07-28 ES ES10806936.0T patent/ES2668079T3/es active Active
- 2010-07-28 CN CN201811078247.XA patent/CN109172813B/zh active Active
- 2010-07-28 JP JP2012523006A patent/JP5815521B2/ja active Active
- 2010-07-28 RU RU2015141669A patent/RU2733466C2/ru active
- 2010-07-28 NZ NZ713967A patent/NZ713967A/en unknown
- 2010-07-28 NZ NZ623910A patent/NZ623910A/en active IP Right Revival
- 2010-07-28 MX MX2017000266A patent/MX379016B/es unknown
- 2010-07-28 CA CA2768999A patent/CA2768999C/en active Active
- 2010-07-28 CA CA3120503A patent/CA3120503A1/en not_active Abandoned
- 2010-07-28 AU AU2010281403A patent/AU2010281403B2/en active Active
- 2010-07-28 EP EP18161509.7A patent/EP3354277B1/en active Active
- 2010-07-28 ES ES18161509T patent/ES2887552T3/es active Active
- 2010-07-28 WO PCT/US2010/043586 patent/WO2011017177A1/en not_active Ceased
- 2010-07-28 MX MX2015000528A patent/MX344786B/es unknown
- 2010-07-28 NZ NZ598156A patent/NZ598156A/en not_active Application Discontinuation
- 2010-07-28 CN CN201080042877.7A patent/CN102686237B/zh active Active
- 2010-07-28 PL PL18161509T patent/PL3354277T3/pl unknown
- 2010-07-28 US US12/845,653 patent/US20110027254A1/en not_active Abandoned
-
2012
- 2012-01-26 IL IL217774A patent/IL217774B/en active IP Right Grant
- 2012-01-27 ZA ZA2012/00704A patent/ZA201200704B/en unknown
- 2012-03-01 CO CO12036036A patent/CO6660423A2/es unknown
-
2014
- 2014-01-31 US US14/169,628 patent/US11571466B2/en active Active
-
2015
- 2015-03-09 JP JP2015045704A patent/JP6066503B2/ja active Active
- 2015-07-31 ZA ZA2015/05556A patent/ZA201505556B/en unknown
-
2016
- 2016-02-05 AU AU2016200739A patent/AU2016200739B2/en active Active
- 2016-07-11 JP JP2016136753A patent/JP6378257B2/ja active Active
-
2018
- 2018-01-04 JP JP2018000259A patent/JP2018077246A/ja active Pending
- 2018-05-11 AU AU2018203308A patent/AU2018203308B2/en active Active
- 2018-05-16 IL IL259413A patent/IL259413B/en active IP Right Grant
-
2019
- 2019-10-28 JP JP2019194895A patent/JP2020033367A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262668A (en) | Preparations for the treatment of Gaucher disease | |
| HRP20190214T1 (hr) | Pripravci i metode za liječenje purpure | |
| EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
| EP2603199A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
| IL218987A0 (en) | Methods and compositions for treating cancer | |
| IL215932A0 (en) | Compositions and methods for treating burns | |
| IL209032A0 (en) | Compositions and methods for treating digestive disorders | |
| ZA201200263B (en) | Compounds and methods for treating influenza | |
| IL218212A0 (en) | Therapeutic methods and compositions | |
| ZA201102765B (en) | Process for extracting cardiac glycodides and compositions | |
| EP2411006A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS | |
| IL210097A0 (en) | Compositions and methods for treating unfluenza | |
| IL215856A0 (en) | Compositions and methods for treatment of cardiovascular disease | |
| GB0903299D0 (en) | Composition and methods | |
| GB0912468D0 (en) | Composition and method | |
| EP2485738A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF ADIPOSITAS | |
| IL218726A0 (en) | Methods and pharmaceutical compositions for treating down syndrome | |
| GB0901494D0 (en) | Compositions and Methods | |
| EP2512504A4 (en) | COMPOSITION AND THERAPEUTIC METHOD | |
| EP2461870A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
| EP2462131A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID | |
| GB0901667D0 (en) | Composition and method | |
| GB0907093D0 (en) | Tissue softening methods and compositions | |
| GB0903913D0 (en) | Compositions and methods | |
| GB0909720D0 (en) | Compositions and methods |